Antimicrobial Activity of Telavancin Tested Against a Global Collection of Gram-Positive Pathogens, Including Multidrug-Resistant Isolates (2015-2017).

This study evaluated the antimicrobial activity of telavancin against a large collection of Gram-positive pathogens of clinical importance, which were collected worldwide from 2015 through 2017, including methicillin-resistant (MRSA), coagulase-negative staphylococci, spp., β-hemolytic streptococci (BHS), , and viridans group streptococci (VGS). This report completes 7 years of continuous surveillance data for telavancin using the approved reference method for testing methodology that includes the addition of polysorbate 80. For isolates collected from 2015 through 2017, telavancin exhibited potent activity against the following species and groups that have Clinical and Laboratory Standards Institute (CLSI)-approved interpretive criteria: MRSA (MIC value, 0.06 μg/mL; 100% susceptible), vancomycin-susceptible (MIC value, 0.25 μg/mL; 99.9% susceptible), BHS (MIC value, 0.03 μg/mL; 100% susceptible), and VGS (MIC value, 0.03 μg/mL; 99.0% susceptible). Importantly, telavancin maintained excellent antimicrobial activity against multidrug-resistant subsets of these pathogen groups and against ceftaroline-nonsusceptible (telavancin MIC value, 0.06 μg/mL; 100% susceptible) and ceftaroline-resistant (telavancin MIC value, 0.12 μg/mL; 100% susceptible) isolates.